Highlights
In the randomized phase 2 Intergroup E4412 trial, adding ipilimumab to brentuximab vedotin and nivolumab did not significantly improve the primary end point of complete response rate in relapsed/refractory classic Hodgkin lymphoma.
Complete response rates were high in both arms: 64.7% with brentuximab vedotin plus nivolumab and 70.3% with brentuximab vedotin plus ipilimumab and nivolumab, with no statistically significant difference.
Overall progression-free survival was also not significantly different between treatment groups after a median follow-up of 38.0 months.
An exploratory but clinically interesting signal emerged in patients who did not undergo stem cell transplantation after initial response: 36-month progression-free survival was 73.0% with the triplet versus 45.8% with the doublet, suggesting a possible role for intensified checkpoint-based induction in patients seeking to defer or avoid transplant.
Why This Study Matters
Relapsed classic Hodgkin lymphoma is one of the most immunologically responsive lymphoid malignancies, yet treatment decisions after first relapse remain nuanced. Many patients can still be cured, but the therapeutic path often involves balancing depth of remission, transplant eligibility, prior brentuximab vedotin exposure, cumulative toxicity, and patient preference. Salvage therapy that produces high complete response rates before autologous stem cell transplantation is especially attractive because metabolic complete remission prior to transplant has been associated with improved outcomes.
Checkpoint inhibition has reshaped the management of relapsed Hodgkin lymphoma because Reed-Sternberg cells frequently exploit the PD-1 pathway through 9p24.1 amplification and related mechanisms. Nivolumab and pembrolizumab have established activity in the relapsed setting, while brentuximab vedotin targets CD30, a near-universal marker in classic Hodgkin lymphoma. Combining these approaches is biologically appealing: one agent directly delivers cytotoxic payload to CD30-positive cells, while the checkpoint inhibitor restores antitumor immunity. Adding CTLA-4 blockade with ipilimumab offers a further theoretical enhancement of T-cell priming and expansion, but also raises concern for incremental immune toxicity.
The E4412 study was therefore clinically important for two reasons. First, it directly tested whether triplet immunotherapy plus antibody-drug conjugate therapy could outperform a highly active doublet. Second, it provided longer-term follow-up relevant to a question increasingly faced in clinic: whether some patients with strong responses to modern salvage regimens might safely defer consolidative transplant.
Study Design
Trial overview
E4412 was a phase 1/2 Intergroup study evaluating checkpoint blockade with nivolumab and ipilimumab combined with brentuximab vedotin in relapsed/refractory classic Hodgkin lymphoma. The report highlighted here focuses on the randomized phase 2 portion.
Population
A total of 147 patients aged 12 years or older were randomized between two treatment approaches, and 132 patients were included in the primary efficacy analysis. Patients had relapsed or refractory classic Hodgkin lymphoma, representing a population in whom effective salvage therapy is clinically central.
Interventions and comparator
The two randomized treatment arms were brentuximab vedotin plus nivolumab and brentuximab vedotin plus ipilimumab and nivolumab. In practical terms, the study asked whether adding CTLA-4 inhibition to a PD-1 inhibitor plus CD30-directed therapy would produce meaningfully deeper responses and longer disease control.
End points
The primary end point was complete response rate. Key secondary assessments included progression-free survival and safety. The study also included a planned comparison by stem cell transplantation status, a particularly relevant feature given how often response to salvage therapy informs the next therapeutic step.
Key Results
Primary end point: complete response
The study did not meet its primary end point. Complete response rate was 64.7% with brentuximab vedotin plus nivolumab, with a confidence interval of 52.2% to 75.9%, and 70.3% with brentuximab vedotin plus ipilimumab and nivolumab, with a confidence interval of 57.6% to 81.1%. The one-sided P value was .29, indicating no statistically significant superiority of the triplet over the doublet.
These findings are noteworthy because both arms achieved high complete response rates, underscoring the potency of checkpoint-based salvage treatment in classic Hodgkin lymphoma. At the same time, the absence of a significant gain from ipilimumab suggests that biologic plausibility does not automatically translate into measurable clinical advantage when added to an already active doublet.
Progression-free survival in the overall study population
After a median survival follow-up of 38.0 months, with an interquartile range of 32.6 to 48.1 months, progression-free survival did not significantly differ between arms. The hazard ratio was 0.78 with a confidence interval of 0.39 to 1.57 and a one-sided P value of .24.
Clinically, this means that even though the numerical trend favored the triplet, the data do not support a clear overall progression-free survival benefit for routine addition of ipilimumab in an unselected relapsed Hodgkin lymphoma population. The wide confidence interval also reflects uncertainty around the effect estimate and the limitations inherent to phase 2 sample size.
Transplant-related outcomes
The transplant analysis is one of the most practical aspects of the study. Fifty-eight patients underwent stem cell transplantation. Among these patients, the 36-month progression-free survival measured from transplantation was greater than 90% in both arms. This is reassuring and supports the concept that checkpoint antibody-drug conjugate induction can serve effectively as a bridge to transplant.
These results align with current practice patterns in which achieving a deep remission before autologous transplant remains a key therapeutic goal in eligible patients. The excellent post-transplant progression-free survival in both study arms implies that either regimen can be considered an active pre-transplant platform, though comparative transplant-specific conclusions should remain cautious because this was not a randomized post-transplant question.
Patients who did not undergo stem cell transplantation
The most provocative finding came from the subgroup of 66 patients who were progression-free after the first scan and did not undergo stem cell transplantation. In this group, 36-month progression-free survival was 73.0%, with a confidence interval of 54.5% to 85.0%, for brentuximab vedotin plus ipilimumab and nivolumab, compared with 45.8%, with a confidence interval of 26.3% to 63.4%, for brentuximab vedotin plus nivolumab. The hazard ratio was 0.45 with a confidence interval of 0.19 to 1.08 and a one-sided P value of .03.
This does not overturn the negative primary end point, but it introduces a potentially important hypothesis: the triplet may improve durability of disease control in carefully selected patients who achieve early disease control and elect not to proceed immediately to transplant. Because this was not the primary efficacy population and the confidence interval crosses 1.0, the finding should be interpreted as signal-generating rather than definitive. Still, for clinicians counseling patients who are reluctant to undergo transplant or who may not be ideal transplant candidates, the magnitude of difference is difficult to ignore.
Safety and Tolerability
Safety is central when considering escalation from dual to triple immune-based therapy. Treatment-related grade 3 or higher toxicities in the adult cohort, excluding rash, were similar between arms: 38.5% with brentuximab vedotin plus nivolumab and 39.3% with brentuximab vedotin plus ipilimumab and nivolumab.
The main differentiating toxicity was rash. Grade 3 rash occurred in 24.6% of patients receiving the triplet compared with 9.2% receiving the doublet. This is clinically meaningful. Although rash is often manageable, grade 3 immune-mediated dermatologic toxicity can require treatment interruption, systemic corticosteroids, subspecialty support, and careful reassessment of benefit versus risk. In a disease where the control arm is already highly active, any added toxicity requires a convincing efficacy gain. That gain was not established for the primary end point in this study.
From a practical standpoint, the toxicity profile supports the view that triplet therapy is feasible but not clearly preferable for all patients. The extra immune toxicity, particularly dermatologic toxicity, may be acceptable in selected cases if a clinician is specifically attempting non-transplant disease control, but it is harder to justify as a standard intensification strategy for every patient with relapsed disease.
Clinical Interpretation
What the trial answers clearly
The clearest message is that adding ipilimumab to brentuximab vedotin plus nivolumab should not be regarded as a new universal standard of care for relapsed/refractory classic Hodgkin lymphoma on the basis of these data alone. The triplet failed to demonstrate superior complete response rate and did not significantly improve progression-free survival in the full randomized population.
At the same time, the study confirms the strength of checkpoint-based salvage therapy. Both regimens induced substantial complete remission rates, and patients proceeding to stem cell transplantation had outstanding 3-year progression-free survival. For transplant-eligible patients, this strongly supports antibody-drug conjugate plus checkpoint inhibitor induction as an effective route to autologous transplant.
The biologic and therapeutic rationale for the non-transplant signal
The signal in patients who did not undergo transplant is biologically plausible. Classic Hodgkin lymphoma is exquisitely sensitive to PD-1 blockade because of its immune microenvironment and frequent PD-L1/PD-L2 upregulation. CTLA-4 blockade may complement PD-1 inhibition by broadening T-cell priming and reducing inhibitory signaling earlier in the immune response. In some patients, this may translate less into higher initial radiographic complete response and more into more durable immune surveillance over time.
That distinction matters. Response rate end points, especially complete response at an early landmark, may not fully capture the value of immunotherapy combinations that are more effective at sustaining disease control than at converting partial responses into complete responses quickly. This may partly explain why the trial was negative on its primary end point yet still produced an intriguing durability signal in the non-transplant cohort.
How this fits into current practice
For transplant-eligible patients with relapsed Hodgkin lymphoma, current management generally prioritizes achieving a deep remission and proceeding to autologous stem cell transplantation when appropriate. E4412 supports continued use of checkpoint-based salvage strategies in this setting, but it does not compel routine addition of ipilimumab.
For patients seeking to defer or avoid transplant, the study is more thought-provoking. Shared decision-making in relapsed Hodgkin lymphoma is increasingly individualized, especially in younger patients concerned about fertility, treatment burden, long-term toxicity, or quality of life, and in older or medically frail patients for whom transplant may be less attractive. In such scenarios, a triplet regimen with brentuximab vedotin, nivolumab, and ipilimumab may be considered investigationally attractive, but clinicians should discuss the uncertainty honestly: the signal is promising, not practice-settling.
Strengths and Limitations
Strengths
The study’s strengths include its randomized design, direct comparison against an active and clinically relevant control regimen, inclusion of long enough follow-up to assess durability, and presentation of transplant-stratified outcomes that matter in real-world therapeutic sequencing.
The trial also addressed a contemporary therapeutic question rather than a historical one. Given the established activity of brentuximab vedotin and PD-1 blockade in Hodgkin lymphoma, testing whether CTLA-4 inhibition adds value is exactly the sort of refinement needed as the field moves from proving efficacy to optimizing strategy.
Limitations
Several limitations should temper interpretation. First, this was a phase 2 study and not powered like a definitive phase 3 superiority trial. Second, the primary end point was complete response rate, which may be imperfect for assessing immunotherapy-driven durability. Third, subgroup findings, including the non-transplant signal, are inherently more vulnerable to selection effects and chance, even when planned. The confidence interval around the hazard ratio in the non-transplant cohort crossed 1.0, highlighting residual uncertainty despite the one-sided P value.
Additional questions remain unanswered. Prior exposure patterns, transplant candidacy nuances, PET response kinetics, and longer-term toxicities would all influence how these findings are applied. It is also unclear whether the observed disease-control signal would persist in larger cohorts or against evolving salvage regimens that incorporate newer sequencing strategies.
Implications for Research
E4412 points toward several next steps. One is to design trials specifically for patients who may defer transplant, using progression-free survival or treatment-free survival rather than early complete response as the primary end point. Another is to identify biomarkers that predict who benefits from deeper immune intensification. Given the unique biology of classic Hodgkin lymphoma, tumor microenvironment features, circulating immune markers, or genomic correlates related to antigen presentation and checkpoint dependence may be especially informative.
There is also room to refine toxicity management. If CTLA-4 blockade does contribute to durable control in a subset of patients, alternative dosing, schedule modification, or biomarker-guided selection might improve the therapeutic index.
Bottom Line
The randomized phase 2 E4412 trial did not show that adding ipilimumab to brentuximab vedotin plus nivolumab improves complete response rate in relapsed/refractory classic Hodgkin lymphoma, nor did it demonstrate a significant overall progression-free survival advantage. However, both regimens were highly active, and outcomes after stem cell transplantation were excellent.
The most clinically interesting observation was a potential progression-free survival benefit with the triplet among patients who responded early and did not proceed to transplant. This finding should not yet change standard practice broadly, but it raises an important hypothesis: for selected patients wishing to defer or avoid transplant, more intensive checkpoint-based induction may offer more durable disease control. That question now deserves focused, prospective testing.
Funding and Trial Registration
Trial registration: ClinicalTrials.gov identifier NCT01896999.
The study was reported as an Intergroup phase 1/2 trial. Readers seeking full funding and cooperative group support details should refer to the published article.
Reference
Diefenbach CS, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, Natkunam Y, Scott DW, Ambinder RF, David KA, Advani RH, Bartlett NL, Roberston MA, Thomas SP, Cohen J, Ibrahimi S, Goyal G, Mehta-Shah N, Amengual JE, Forlenza CJ, Cole PD, Duan F, Kelly K, Kahl BS. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026 Apr 30;147(18):2041-2052. PMID: 41662628. Available at: https://pubmed.ncbi.nlm.nih.gov/41662628/
